129885-95-6

Usage

Uses

Used in Pharmaceutical Industry:
3'-Deoxy-3'-fluoro-xylo-uridine is used as an antiviral agent for its ability to inhibit the replication of specific viruses, such as HIV and hepatitis B virus. Its unique structure contributes to its potential as a therapeutic agent in antiviral drug development.
Used in Research and Development:
3'-Deoxy-3'-fluoro-xylo-uridine is utilized as a research tool for studying the structure and function of nucleic acids. Its distinctive chemical properties make it valuable in advancing the understanding of nucleoside analogs and their interactions with biological systems.

Upstream product

• 129885-89-8 1-(3-deoxy-3-fluoro-2,5-di-O-trityl-β-D-xylofuranosyl)uracil 
• 620630-82-2 1,2 5,6-O-di(isopropylidene)-α-D-allofuranose 
• 18530-81-9 1-((3aR,5R,6S,6aS)-6-Fluoro-2,2-dimethyl-tetrahydro-furo[2,3-d][1,3]dioxol-5-yl)-ethane-1,2-diol 
• 70722-99-5 (3aR,5R,6S,6aS)-6-fluoro-2,2-dimethyltetrahydrofuro[2,3-d][1,3]dioxole-5-carbaldehyde 
• 18530-84-2 3-deoxy-3-fluoro-1,2-O-isopropylidene-α-D-xylofuranose 
• 238418-63-8 3-fluoro-α-D-3-deoxy-xylofuranose 

Downstream Products

• 1298015-61-8 1-(5'-O-dimethoxytrityl-3'-deoxy-3'-fluoro-β-D-xylofuranosyl)uracil 
• 1298015-64-1 1-(5'-O-dimethoxytrityl-3'-deoxy-3'-fluoro-2'-cyanoethylphosphoramidite-β-D-xylofuranosyl)uracil 

Relevant academic research and scientific papers

MODIFIED RNAI AGENTS

One aspect of the present invention relates to double-stranded RNAi (dsRNA) duplex agent capable of inhibiting the expression of a target gene in vivo. The dsRNA duplex comprises one or more xylo modifications in one or both strand. Other aspects of the invention relates to pharmaceutical compositions comprising these dsRNA agents suitable for in vivo therapeutic use, and methods of inhibiting the expression of a target gene by administering these dsRNA agents, e.g., for the treatment of various disease conditions.

Anti-HCV nucleoside derivatives

The present invention comprises novel and known purine and pyrimidine nucleoside derivatives which have been discovered to be active against hepatitis C virus (HCV). The use of these derivatives for the treatment of HCV infection is claimed as are the novel nucleoside derivatives disclosed herein.